Opinion|Videos|July 18, 2024
Impact of JAK Inhibitors on Itch and Quality of Life in Atopic Dermatitis
Author(s)Shawn Kwatra, MD
Shawn Kwatra, MD, provides an overview of oral JAK inhibitors for the treatment of atopic dermatitis, highlighting data from clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What characteristics, if any, of oral JAK inhibitors make them an attractive option for improving QoL in patients with AD?
- Discuss clinical trial data with oral JAK inhibitors, upadacitinib and abrocitinib, and improvements in patient-reported outcomes in atopic dermatitis.
- Please review data from real-world studies that have evaluated effectiveness of oral JAK inhibitors (upadacitinib and abrocitinib) through physician and patient-reported outcomes.
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
3
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
4
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
5